Iron absorption and phosphate-lowering effects of ferric citrate hydrate are not influenced by gastric acid secretion inhibitors in patients with chronic kidney disease: a retrospective post hoc analysis

BACKGROUND: Ferric citrate hydrate (FC), an oral iron product is approved as iron preparation for iron deficiency anemia and phosphate binder for chronic kidney disease (CKD). We investigated whether gastric acid secretion inhibitors (GASI) influenced on iron absorption and phosphate-lowering effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Kyoko, Yokoyama, Keitaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Nephrology - Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807476/
https://www.ncbi.nlm.nih.gov/pubmed/35821366
http://dx.doi.org/10.1007/s11255-022-03287-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807476/
https://www.ncbi.nlm.nih.gov/pubmed/35821366
http://dx.doi.org/10.1007/s11255-022-03287-1

Ejemplares similares